Exai Bio’s RNA-Based Liquid Biopsy Platform Detects Early Stage Breast Cancer Accurately
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.
Read MorePosted by Andy Lundin | Dec 8, 2023 | Breast |
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.
Read MorePosted by Andy Lundin | Dec 6, 2023 | Sepsis |
Cytovale detailed the publication of a new peer-reviewed study that highlights the need for rapid sepsis testing.
Read MorePosted by Andy Lundin | Dec 6, 2023 | Covid 19 |
The federal government expanded an entirely virtual community health program that offers free COVID-19 health services.
Read MorePosted by Chris Wolski | Dec 6, 2023 | Digital Imaging |
CellNetix Pathology & Laboratories is innovating its practice with digital pathology with the help of Proscia.
Read MorePosted by Chris Wolski | Dec 5, 2023 | Sequencing Systems |
Genomenon, a genomic intelligence company, has launched Genomenon Curate-Pro, a rapid on-demand...
Read More